Apichem Laboratories Profile
Key Indicators
- Authorised Capital ₹ 260.10 Cr
as on 16-11-2024
- Paid Up Capital ₹ 97.10 Cr
as on 16-11-2024
- Company Age 4 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 35.00 Cr
as on 16-11-2024
- Revenue 107.52%
(FY 2023)
- Profit 161.59%
(FY 2023)
- Ebitda 63.91%
(FY 2023)
- Net Worth 2.41%
(FY 2023)
- Total Assets 6.63%
(FY 2023)
About Apichem Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 260.10 Cr and a paid-up capital of Rs 97.10 Cr.
The company currently has active open charges totaling ₹35.00 Cr.
The Key Managerial Personnel (KMP) at Apichem Laboratories Private Limited India is Birendra Nath as COMPANY SECRETARY. Achyuth Manne and Nikhil Mandha serve as directors at the Company.
- CIN/LLPIN
U24230TG2020PTC138207
- Company No.
138207
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Jan 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Apichem Laboratories?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Birendra Nath | Company Secretary | 12-Aug-2024 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Achyuth Manne  | Director | 06-Jan-2020 | Current |
| Nikhil Mandha | Director | 06-Jan-2020 | Current |
Financial Performance and Corporate Structure Insights of Apichem Laboratories.
Apichem Laboratories Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 107.52% increase. The company also saw a substantial improvement in profitability, with a 161.59% increase in profit. The company's net worth moved up by a moderate rise of 2.41%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Apichem Laboratories?
In 2023, Apichem Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 17 Mar 2022 | ₹35.00 Cr | Open |
How Many Employees Work at Apichem Laboratories?
Apichem Laboratories has a workforce of 87 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Apichem Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Apichem Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
